Capricor Therapeutics Investors Alerted for Class Action Lawsuit Before Deadline#San_Francisco#class_action_lawsuit#Capricor_Therapeutics#FDA_Review
Capricor Therapeutics Investors Alerted for Class Action Lawsuit Before Deadline
Capricor Therapeutics, Inc. investors with significant losses are urged to participate in a class action lawsuit before the September 28 deadline, following recent FDA developments.
third-news.com
September 21, 2026 at 4:17 PM
Capricor Therapeutics Investors Alerted for Class Action Lawsuit Before Deadline#San_Francisco#class_action_lawsuit#Capricor_Therapeutics#FDA_Review
Capricor Therapeutics Faces FDA Review Delay as Investors Prepare for Class Action Deadline#United_States#San_Francisco#deramiocel#Capricor_Therapeutics#FDA_Review
Capricor Therapeutics Faces FDA Review Delay as Investors Prepare for Class Action Deadline
Capricor Therapeutics Inc. is dealing with an FDA review extension for deramiocel amidst an ongoing securities class action. Investors must prepare for a lead plaintiff deadline.
third-news.com
September 17, 2026 at 10:31 PM
Capricor Therapeutics Faces FDA Review Delay as Investors Prepare for Class Action Deadline#United_States#San_Francisco#deramiocel#Capricor_Therapeutics#FDA_Review
ByHeart's Proactive Approach Following FDA's Review of Botulism Outbreak Investigation#USA#New_York#FDA_Review#ByHeart#Clostridium_botulinum
ByHeart's Proactive Approach Following FDA's Review of Botulism Outbreak Investigation
ByHeart provides an update on its response to the 2025 botulism outbreak. The FDA reviews the company's investigation and action plan, paving the way for safe formula production.
third-news.com
August 28, 2026 at 5:55 PM
ByHeart's Proactive Approach Following FDA's Review of Botulism Outbreak Investigation#USA#New_York#FDA_Review#ByHeart#Clostridium_botulinum
Pomerantz Law Firm Investigates Potential Securities Fraud Against Disc Medicine, Inc.#United_States#New_York#Pomerantz_LLP#FDA_Review#Disc_Medicine
Pomerantz Law Firm Investigates Potential Securities Fraud Against Disc Medicine, Inc.
Pomerantz LLP is currently probing claims on behalf of investors of Disc Medicine, Inc. amidst allegations of potential securities fraud. Learn more about the situation.
third-news.com
April 2, 2026 at 2:48 PM
Pomerantz Law Firm Investigates Potential Securities Fraud Against Disc Medicine, Inc.#United_States#New_York#Pomerantz_LLP#FDA_Review#Disc_Medicine
Vanda Pharmaceuticals Urges FDA Review on Generics Approval Decision for Hetlioz®#USA#Washington#Vanda_Pharmaceuticals#Hetlioz#FDA_Review
Vanda Pharmaceuticals Urges FDA Review on Generics Approval Decision for Hetlioz®
Vanda Pharmaceuticals is seeking an FDA review regarding the approval of generic versions of Hetlioz®, citing serious concerns over the decision-making process.
third-news.com
August 21, 2025 at 8:51 PM
Vanda Pharmaceuticals Urges FDA Review on Generics Approval Decision for Hetlioz®#USA#Washington#Vanda_Pharmaceuticals#Hetlioz#FDA_Review
Pomerantz Law Firm Remains Committed to Investors of Capricor Therapeutics Amid Serious Allegations of Fraud#United_States#New_York#Pomerantz_LLP#Capricor_Therapeutics#FDA_Review
Pomerantz Law Firm Remains Committed to Investors of Capricor Therapeutics Amid Serious Allegations of Fraud
Pomerantz LLP is actively investigating serious allegations of fraud against Capricor Therapeutics Inc. for the benefit of its investors.
third-news.com
July 12, 2025 at 2:22 PM
Pomerantz Law Firm Remains Committed to Investors of Capricor Therapeutics Amid Serious Allegations of Fraud#United_States#New_York#Pomerantz_LLP#Capricor_Therapeutics#FDA_Review
Pomerantz Law Firm Investigates Investors' Claims Against Capricor Therapeutics Following FDA Review#USA#New_York#Pomerantz_LLP#Capricor_Therapeutics#FDA_Review
Pomerantz Law Firm Investigates Investors' Claims Against Capricor Therapeutics Following FDA Review
Pomerantz LLP is examining potential securities fraud claims regarding Capricor Therapeutics. Investors affected should reach out for assistance.
third-news.com
June 1, 2025 at 2:24 PM
Pomerantz Law Firm Investigates Investors' Claims Against Capricor Therapeutics Following FDA Review#USA#New_York#Pomerantz_LLP#Capricor_Therapeutics#FDA_Review
Pomerantz Law Firm Launches Investigation into Nyxoah S.A. Investor Claims Amid FDA Review#United_States#New_York#Pomerantz_LLP#Nyxoah_S.A.#FDA_Review
Pomerantz Law Firm Launches Investigation into Nyxoah S.A. Investor Claims Amid FDA Review
Pomerantz LLP acts on behalf of Nyxoah S.A. investors amid concerns over potential securities fraud linked to FDA review delays.
third-news.com
May 12, 2025 at 9:53 PM
Pomerantz Law Firm Launches Investigation into Nyxoah S.A. Investor Claims Amid FDA Review#United_States#New_York#Pomerantz_LLP#Nyxoah_S.A.#FDA_Review